Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Connie R. Jiménez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3103-4508; OpenAlex author ID A5084043525. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Co-author DOI 10.1002/1878-0261.13625↗
  2. Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2023.112581↗
  3. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-021-01892-z↗
  4. Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers. Last author DOI 10.1007/s13402-020-00548-y↗
  5. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. Co-author DOI 10.1172/jci.insight.138290↗
  6. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Co-author DOI 10.1634/theoncologist.2019-0680↗
  7. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Co-author DOI 10.1177/1758835919841233↗
  8. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Last author DOI 10.1016/j.semcancer.2017.03.008↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elisa Giovannetti · 8 shared papers, 2017–2024 · strength 0.92
  2. Maarten F. Bijlsma · 8 shared papers, 2017–2024 · strength 0.92
  3. Tessa Y. S. Le Large · 6 shared papers, 2017–2021 · strength 0.57
  4. Geert Kazemier M · 6 shared papers, 2017–2021 · strength 0.57
  5. Hanneke W.M. van Laarhoven · 5 shared papers, 2017–2021 · strength 0.46
  6. Andrea Vallés‐Martí · 3 shared papers, 2020–2024 · strength 0.46
  7. Niccola Funel · 4 shared papers, 2019–2021 · strength 0.39
  8. Giulia Mantini · 2 shared papers, 2020–2023 · strength 0.27
  9. Joanne Verheij · 1 shared paper, 2024 · strength 0.20
  10. Frederike Dijk · 1 shared paper, 2024 · strength 0.20
  11. Btissame El Hassouni · 2 shared papers, 2019–2021 · strength 0.19
  12. Laura L. Meijer · 2 shared papers, 2020 · strength 0.19
  13. Paul Manoukian · 1 shared paper, 2023 · strength 0.16
  14. Tonny Lagerweij · 1 shared paper, 2021 · strength 0.11
  15. Luca Morelli · 1 shared paper, 2021 · strength 0.11
  16. Mjriam Capula · 1 shared paper, 2020 · strength 0.11
  17. Freek D. Daams · 1 shared paper, 2020 · strength 0.09
  18. Lenka N.C. Boyd · 1 shared paper, 2020 · strength 0.09
  19. Babs M. Zonderhuis · 1 shared paper, 2020 · strength 0.09
  20. Kenneth P. Olive · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.